ArticleBlood advances2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.Haematologica · 2022Pooled it
- Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.Journal of geriatric oncology · 2024Trial
- Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.Haematologica · 2026Article
- Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia.Haematologica · 2026Article
- Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.British journal of haematology · 2026Article
- The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026Review
- Article
- Review
- Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach.Internal medicine journal · 2025Article
- NACC1 accelerates the progression of AML by regulating the ADAM9/PI3K/AKT axis.International journal of medical sciences · 2025Article
- Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.Therapeutic advances in hematology · 2025Article
- Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death.Frontiers in immunology · 2025Article
- Clinical Peptidomics in Acute Leukemias: Current Advances and Future Perspectives.Journal of proteome research · 2024Review
- Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.Annals of hematology · 2024Article
- The approach of HMA plus VEN with or without BMT for all patients with AML.Hematology. American Society of Hematology. Education Program · 2023Article
- Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.JCO oncology practice · 2023Article
- Facility type and cancer outcomes in the United States.Annals of cancer epidemiology · 2023Article
- [Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Membrane-Wrapped Nanoparticles for Enhanced Chemotherapy of Acute Myeloid Leukemia.ACS biomaterials science & engineering · 2022Article
- Are We Moving the Needle for Patients withCancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Cytarabine-anthracycline based intensive induction chemotherapy (IC) remains the standard of care for remission induction among fit patients with newly diagnosed acute myeloid leukemia (AML) in the United States (US). However, the mortality rate outside of clinical IC trials, predictors of death, and resource utilization during admission for IC have not been thoroughly examined. We used the Premier Healthcare database to identify adult patients (aged 18-89 years) treated with cytarabine-anthracycline-based IC during their first recorded inpatient stay for AML during the contemporary period of 2010 to 2017. We identified factors associated with inpatient death or discharge to hospice, using multivariable logistic regression models. We also assessed the patterns of inpatient healthcare resource utilization. A total of 6442 patients with AML from 313 hospitals who were treated with IC were identified. Median age was 61 years (interquartile range [IQR], 50-68 years), and 56% were men. Median length of stay was 29 (IQR, 25-38) days, with rates of in-hospital death and discharge to hospice of 12.3% and 3.7% (17.9% and 6.3% among patients aged ≥65 years), respectively. Predictors of in-hospital death or discharge to hospice included older age, geographic region, and lower hospital volume. During admission, 28.0%, 12.6%, and 4.0% of patients required treatment in intensive care units, mechanical ventilation, and dialysis, respectively. Despite improvements in supportive care in the contemporary era, inpatient mortality during first hospitalization for adult patients with AML treated with IC in the US remains high particularly among older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.